+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Transfection Reagents and Equipment Market by Product and Geography - Forecast and Analysis 2020-2024

  • ID: 4876582
  • Report
  • November 2019
  • Region: Global
  • 148 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Transfection Reagents and Equipment Market: About this market
The transfection reagents and equipment market analysis considers sales from both reagents and equipment products. Our study also finds the sales of transfection reagents and equipment in Asia, Europe, North America, and ROW. In 2019, the reagents segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing commercial adoption and low prices of transfection reagents will play a significant role in the reagents segment to maintain its market position. Also, our global transfection reagents and equipment market report looks at factors such as high prevalence and incidence of cancer, improvement in healthcare infrastructure in emerging economies, and rising demand for timely disease diagnosis. However, the risk associated with the extraction of DNA and RNA, strict compliance regarding the transportation of genetically modified organisms, and intense competition among vendors may hamper the growth of the transfection reagents and equipment industry over the forecast period.

Global Transfection Reagents and Equipment Market: Overview

Rising demand for timely disease diagnosis
Early diagnosis diseases are necessary among patients with a high risk of hereditary conditions. It requires genetic tools to facilitate diagnostic tests such as next-generation sequencing and DNA microarrays. This is driving the demand for transfection reagents as they are used for conducting genetic variation testing procedures. They help in identifying risks of developing diseases such as Alzheimer’s disease, Parkinson’s disease, and cancer. Thus, the rising demand for timely disease diagnosis will lead to the expansion of the global transfection reagents and equipment market at a CAGR of over 6% during the forecast period.

Rise in clinical trials in developing nations
Transfection reagents are being increasingly used in preclinical studies as well as clinical trials to support the development of novel therapies based on the delivery of nucleic acids. Pharmaceutical companies conduct clinical trials to comply with stringent regulations and reduce their drug development costs. The rise in the number of clinical trials in developing countries can be attributed to factors such as access to a large patient pool, friendly market reforms, strong intellectual property and clinical trial infrastructure, and availability of skilled workforce. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global transfection reagents and equipment market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading transfection reagents and equipment manufacturers, that include Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Lonza Group Ltd., MaxCyte Inc., Merck KGaA, Polyplus-transfection SA, Promega Corp., QIAGEN NV, and Thermo Fisher Scientific Inc.

Also, the transfection reagents and equipment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Reagents - Market size and forecast 2019-2024
  • Equipment - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS
  • Rise in clinical trials in developing nations
  • Geopolitical uncertainties
  • Rising healthcare expenditures

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA
  • Polyplus-transfection SA
  • Promega Corp.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

List of Exhibits
Exhibit 01: Global healthcare equipment market
Exhibit 02: Segments of global healthcare equipment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendor key offerings
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Product - Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Reagents - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Reagents - Year-over-year growth 2020-2024 (%)
Exhibit 22: Equipment - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Equipment - Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Agilent Technologies Inc. - Vendor overview
Exhibit 49: Agilent Technologies Inc. - Business segments
Exhibit 50: Agilent Technologies Inc. - Organizational developments
Exhibit 51: Agilent Technologies Inc. - Geographic focus
Exhibit 52: Agilent Technologies Inc. - Segment focus
Exhibit 53: Agilent Technologies Inc. - Key offerings
Exhibit 54: Agilent Technologies Inc. - Key customers
Exhibit 55: Bio-Rad Laboratories Inc. - Vendor overview
Exhibit 56: Bio-Rad Laboratories Inc. - Product segments
Exhibit 57: Bio-Rad Laboratories Inc. - Organizational developments
Exhibit 58: Bio-Rad Laboratories Inc. - Geographic focus
Exhibit 59: Bio-Rad Laboratories Inc. - Segment focus
Exhibit 60: Bio-Rad Laboratories Inc. - Key offerings
Exhibit 61: Bio-Rad Laboratories Inc. - Key customers
Exhibit 62: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 63: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 68: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 69: Lonza Group Ltd. - Vendor overview
Exhibit 70: Lonza Group Ltd. - Business segments
Exhibit 71: Lonza Group Ltd. - Organizational developments
Exhibit 72: Lonza Group Ltd. - Geographic focus
Exhibit 73: Lonza Group Ltd. - Segment focus
Exhibit 74: Lonza Group Ltd. - Key offerings
Exhibit 75: Lonza Group Ltd. - Key customers
Exhibit 76: MaxCyte Inc. - Vendor overview
Exhibit 77: MaxCyte Inc. - Business segments
Exhibit 78: MaxCyte Inc. - Organizational developments
Exhibit 79: MaxCyte Inc. - Key offerings
Exhibit 80: MaxCyte Inc. - Key customers
Exhibit 81: Merck KGaA - Vendor overview
Exhibit 82: Merck KGaA - Business segments
Exhibit 83: Merck KGaA - Organizational developments
Exhibit 84: Merck KGaA - Geographic focus
Exhibit 85: Merck KGaA - Segment focus
Exhibit 86: Merck KGaA - Key offerings
Exhibit 87: Merck KGaA - Key customers
Exhibit 88: Polyplus-transfection SA - Vendor overview
Exhibit 89: Polyplus-transfection SA - Product segments
Exhibit 90: Polyplus-transfection SA - Organizational developments
Exhibit 91: Polyplus-transfection SA - Key offerings
Exhibit 92: Polyplus-transfection SA - Key customers
Exhibit 93: Promega Corp. - Vendor overview
Exhibit 94: Promega Corp. - Product segments
Exhibit 95: Promega Corp. - Organizational developments
Exhibit 96: Promega Corp. - Key offerings
Exhibit 97: Promega Corp. - Key customers
Exhibit 98: QIAGEN NV - Vendor overview
Exhibit 99: QIAGEN NV - Business segments
Exhibit 100: QIAGEN NV - Organizational developments
Exhibit 101: QIAGEN NV - Geographic focus
Exhibit 102: QIAGEN NV - Segment focus
Exhibit 103: QIAGEN NV - Key offerings
Exhibit 104: QIAGEN NV - Key customers
Exhibit 105: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 106: Thermo Fisher Scientific Inc. - Business segments
Exhibit 107: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 108: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 109: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 110: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 111: Thermo Fisher Scientific Inc. - Key customers
Exhibit 112: Validation techniques employed for market sizing
Exhibit 113: Definition of market positioning of vendors
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA
The following companies as the key players in the global transfection reagents and equipment market: Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Lonza Group Ltd., MaxCyte Inc., Merck KGaA, Polyplus-transfection SA, Promega Corp., QIAGEN NV, and Thermo Fisher Scientific Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rise in clinical trials in developing nations.”

According to the report, one of the major drivers for this market is the rising demand for timely disease diagnosis.

Further, the report states that one of the major factors hindering the growth of this market is strict compliance regarding the transportation of genetically modified organisms.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA
  • Polyplus-transfection SA
  • Promega Corp.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown